Targeting PVR (CD155) and its receptors in anti- tumor therapy (CROSBI ID 274650)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Kučan Brlić, Paola ; Lenac Roviš, Tihana ; Cinamon, Guy ; Tsukerman, Pini ; Mandelboim, Ofer ; Jonjić, Stipan
engleski
Targeting PVR (CD155) and its receptors in anti- tumor therapy
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.
PVR ; tumor ; immunotherapy ; checkpoint ; TIGIT ; poliovirus
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
16
2018.
40-52
objavljeno
1672-7681
2042-0226
10.1038/s41423-018-0168-y
Povezanost rada
Temeljne medicinske znanosti